Longitudinal interferon-β effects in multiple sclerosis: Differential regulation of IL-10 and IL-17A, while no sustained effects on IFN-γ, IL-4 or IL-13

JOURNAL OF THE NEUROLOGICAL SCIENCES

卷:325

Article

Kvarnstrom, M.¹  Ydrefors, J.^1,2  Ekerfelt, C.¹  Vrethem, M.^1,2  Ernerudh, J.^1,3 

[1] Linkoping Univ, Fac Hlth Sci, Dept Clin & Expt Med, S-58185 Linkoping, Sweden

[2] Cty Council Ostergotland, Dept Neurol & Neurophysiol, S-58185 Linkoping, Sweden

[3] Cty Council Ostergotland, S-58185 Linkoping, Sweden

关键词: Multiple sclerosis;    Interferon-beta;    Cytokines;    IL-4;    IL-17;    IL-10;    Responder;   

DOI  :  10.1016/j.jns.2012.12.001

来源: Elsevier

【 摘 要 】

Background: Recent studies in experimental models and in vitro indicate lowering of IL-17/Th17 as an important mechanism of interferon-beta (IFN-beta) treatment in multiple sclerosis (MS). Material and methods: In this longitudinal study of MS patients (n=25), spontaneous and myelin antigen-induced secretion of IL-4, IFN-gamma and IL-10 (ELISPOT), mitogen stimulated secretion of IL-13 and IL-17A (ELISA) and circulating cytokine levels (Luminex) were recorded at inclusion and after 1.5, 3, 6 and 12 months of IFN-beta treatment. Results: Early changes were noted for IL-4. while after one year of treatment the only recorded significant effects were a decrease in secreted IL-17A levels and an increase in IL-10 secreting cells. While IL-17A levels tended to be higher in non-responders (n=8), the decrease in IL-17A levels seemed to be more pronounced in responders (n=17) showing significantly lower IL-17A levels after one year as compared with non-responders. Conclusion: IFNI-beta. treatment seems to mainly affect IL-17/IL-10-associated pathways rather than the IFN-gamma IL-4 axis. (C) 2012 Elsevier B.V. All rights reserved.

【 授权许可】

Free